fbpx
May 16, 2023

Novel Insights on Takotsubo Could Lead to New Therapies Novel Insights on Takotsubo Could Lead to New Therapies

New mechanisms underlying Takotsubo syndrome, often dubbed “broken heart syndrome,” are suggested from hemodynamic studies, which could lead to new treatment strategies for the condition. Takotsubo […]
May 16, 2023

tDCS Produces Encouraging Results in PTSD tDCS Produces Encouraging Results in PTSD

Psychotherapy is one of the two main treatments for posttraumatic stress disorder (PTSD). The other is pharmacologic therapy, and selective serotonin reuptake inhibitors (SSRIs) are the […]
May 16, 2023

iSlim, LLC – 655819 – 05/03/2023

Delivery Method: Via Email Product: Drugs Recipient: Recipient Name Sasha Sans iSlim, LLC 3001 S. Ocean Dr. Apt 1639Hollywood, FL 33019United States [email protected] Issuing Office: Division […]
May 16, 2023

Pharmedica USA, LLC – 648269 – 04/28/2023

Delivery Method: VIA UNITED PARCEL SERVICE AND VIA E-MAIL Product: Drugs Recipient: Recipient Name Mr. Fida M. Abuhmeidan Recipient Title Chief Executive Officer (CEO) Pharmedica USA, […]
May 16, 2023

Sorcerz.com – 656021 – 04/19/2023

Product: Drugs Recipient: Sorcerz.com United States Issuing Office: Center for Drug Evaluation and Research | CDER United States FROM: The United States Food and Drug Administration […]
May 16, 2023

EarthLab, Inc., dba Wise Woman Herbals – 634872 – 04/27/2023

Delivery Method: Overnight Delivery Product: DrugsFood & Beverages Recipient: Recipient Name Bryan C. Bast Recipient Title Interim Chief Executive Officer EarthLab, Inc., dba Wise Woman Herbals […]
May 16, 2023

New Trials in Breast Cancer: Could Your Patient Benefit? New Trials in Breast Cancer: Could Your Patient Benefit?

Several new clinical trials in breast cancer have opened in recent months. Maybe one of your patients could benefit from enrolling. Locally advanced unresectable or metastatic […]
May 16, 2023

New HER2 Drug for Breast Cancer Stalled by FDA New HER2 Drug for Breast Cancer Stalled by FDA

A new drug for breast cancer that was approaching the market in the United States has been stalled: Trastuzumab duocarmazine (developed by Byondis) was awaiting approval […]
May 16, 2023

Yes, Screening for Breast Cancer at 40 Makes Sense, But We Can Do More

Breast cancer survival rates have come a long way in the last several decades. According to the American Cancer Society, the 5-year survival rate for contained […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0